TY - JOUR
T1 - Management and diagnosis of fatty liver disease
AU - Schneier, Amanda Tamar
AU - Citti, Caitlin Colleen
AU - Dieterich, Douglas T.
N1 - Publisher Copyright:
© 2015 Informa UK, Ltd.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Nonalcoholic fatty liver disease is a common cause of chronic liver disease and has been an increasingly studied topic of research as the obesity epidemic has been growing. There is a significant morbidity and mortality with uncontrolled steatohepatitis, which can progress to fibrosis, cirrhosis and hepatocellular carcinoma. The prevalence of this disease has been estimated to be roughly one-third of the western population, thought to be largely due to diet and sedentary lifestyle. Several treatments have been studied including vitamin E, insulin-sensitizing agents and ursodeoxycholic acid; however, the only treatment shown to improve the histologic changes of nonalcoholic fatty liver disease is weight loss. Given the proven benefit of weight loss, there may be reason to screen at-risk populations; however, limited availability of other disease-modifying treatments may limit the cost-benefit ratios. A better understanding of the diagnosis and management of this condition is required to alter the course of this modifiable disease.
AB - Nonalcoholic fatty liver disease is a common cause of chronic liver disease and has been an increasingly studied topic of research as the obesity epidemic has been growing. There is a significant morbidity and mortality with uncontrolled steatohepatitis, which can progress to fibrosis, cirrhosis and hepatocellular carcinoma. The prevalence of this disease has been estimated to be roughly one-third of the western population, thought to be largely due to diet and sedentary lifestyle. Several treatments have been studied including vitamin E, insulin-sensitizing agents and ursodeoxycholic acid; however, the only treatment shown to improve the histologic changes of nonalcoholic fatty liver disease is weight loss. Given the proven benefit of weight loss, there may be reason to screen at-risk populations; however, limited availability of other disease-modifying treatments may limit the cost-benefit ratios. A better understanding of the diagnosis and management of this condition is required to alter the course of this modifiable disease.
KW - NAFLD
KW - NASH
KW - fatty liver disease
KW - review
KW - steatohepatitis
UR - http://www.scopus.com/inward/record.url?scp=84928563580&partnerID=8YFLogxK
U2 - 10.1586/17474124.2015.1003209
DO - 10.1586/17474124.2015.1003209
M3 - Review article
C2 - 25716275
AN - SCOPUS:84928563580
SN - 1747-4124
VL - 9
SP - 671
EP - 683
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
IS - 5
ER -